Issue 24 | 2016
Get instant access to latest e-book

latest news


Sep 2016

Evotec Enters into Strategic Multi-Target Alliance with C4X Discovery

Evotec AG announced a multitarget collaboration with CX Discovery Holdings plc CXD The new agreement builds on the successful research collaboration with CXD announced in January and will see CXD and Evotec work together to develop new small molecule drugs across a range of targets therap..


Sep 2016

FDA approves expanded use of Vertex Pharma's cystic fibrosis drug

Vertex Pharamceuticals Inc said the US Food and Drug Administration expanded the use of its cystic fibrosis drug to treat a new subgroup of patients with the rare genetic disorder The company however cut its sales forecast for the drug Orkambi sending its shares down as much as percent in aftermarket trading on Wednesday Vertex cited a slowerth..


Sep 2016

Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration

Zymeworks Inc a clinicalstage biopharmaceutical company discovering and developing innovative multifunctional proteinbased therapeutics including bispecific antibodies and drug conjugates for the treatment of cancer and Daiichi Sankyo Company Limited hereafter Daiichi Sankyo announced today that they have entered into ..


Sep 2016

Pfizer Completes Acquisition of Medivation

Pfizer Inc announced the successful completion of its acquisition of Medivation Inc As of the tender offer expiration shares of Medivation common stock were validly tendered representing approximately of the shares outstanding and have been accepted for payment under the terms of the tender offer for per share in ca..

events

28 - 30

Sep 2016

6th Pharmacovigilance Congress

OMICS International
Toronto, Ontario

29 - 30

Sep 2016

Signal Detection & Management Strategies

Le Meridien Parkhotel Frankfurt


Sep 2016

Dates Announced For MEDICAL FAIR THAILAND 2017

The th edition of MEDICAL FAIR THAILAND the leadin..


Sep 2016


knowledge bank

  • interviews

    Datwyler Pharma Packaging

    Senior Manager Global Scientific Affairs
    Renaud Janssen, Ph.D. is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging. He frequently presents on international conferences on subjects related to elastomeric and aluminium/plastic closures for pharm..

  • Articles

    When Orphan Drugs Make All the Difference

    Orphan drugs those medications that are typically produced in small quantities for limited patient populations are growing in importance worldwide Once largely considered too costly to produce given the limited number of patients affected by a particular disease new technology and new breakthroughs in biopharma have changed the landscape allowing more orphan drugs to be produced than ever before t..

  • Research Insights

    Temporal Trends And Factors Associated With Cardiovascular Drug Development, 1990 To 2012

    Summary Cardiovascular disease remains a leading cause of death but stakeholders have recently raised concerns about the pace of innovation and investment in developing new therapeutics Here the authors characterized temporal trends in cardiovascular research and development over the past decades and the likelihood of successful completion of preapproval clinical trials The authors also evaluated the reasons for discontinuation novelty and rate..

editorial Section

  • Competing on Alignment

    SWOT is both the most powerful and least understood strategic management tool Used correctly it translates the outputs of many other market analyses into a small number of key issues..

  • Future Trends in Ion Channel and Solute Transporter Drug Discovery

    Gene family members of the ion channel and solute transporter SLC families represent both historical targets of pharmaceutical significance and serve as exciting opportunities for current and future therapeutic development The common property of ion movement for many of the SLCs lends itself to considering platforms used in ion channel research to enable early drug discovery In addition the convergence of advances in both genetic analysis and assay technology bodes well for the identification of the next generation of ion channel and transporterbased drugs in the near future..

  • Issues & Concerns in Conducting Clinical Trials in India

    Issues like approval delays deficiencies of functioning of CROs and other stake holders liabilities and compensation to injured subjects insurance issues etc still remain in India which has made multinational companies to rethink on opting for India to conduct clinical trials in India recently There is a need for a law to ensure that the people who undergo clinical trials are not exploited and should be well informed about risk as well to provide..

  • Innovation Challenges in Manufacturing

    Most firms in the pharmaceutical industry think globally to expand demand for their products There are amenities from which firms leverage to launch a strategy to gain global market share These amenities include the regulatory dimension which helps reassign resources within and outside the firm..

  • Quality by Design

    The article presents a novel approach to applying Quality by Design QbD principles to the development of analytical methods Common critical parameters in HPLC gradient time temperature pH of the aqueous eluent and stationary phase are evaluated within the Quality by Design framework It is useful for the robust analytical method development and Design Space optimisation..

  • Peptides Remain a Growth Story

    Cloud solutions offer immediate returns in improving operational performance and reducing costs Multiple approaches to cloud solutions will be needed to satisfy life science industry needs complicating the development of a coherent cloud strategy..